Biomarin is a fast growing biopharmaceutical company developing treatments for serious unmet medical conditions and rare diseases. Biomarin aims to develop products that are ‘first-to-market’ and ‘best-in-class’ among competitor medications.
Strongly developing since its establishment in 1997, Biomarin is publicly traded and employees over 1,300 people worldwide. The company delivers medications to over 40 countries worldwide and achieved revenues of $548.5m in 2013.
Biomarin brings to the pharmaceutical industry five approved products that amongst them treat them a number of rare conditions:
- VIMIZIM™ (elosulfase alfa) for Morquio A syndrome (MPS IVA)
- Kuvan® (sapropterin dihydrochloride) Tablets for PKU
- Naglazyme® (galsulfase) for MPS VI
- Aldurazyme® (laronidase) for MPS I
- Firdapse®(currently approved in the EU only) (amifampridine phosphate) for LEMS
The company is also developing a number of pre-clinical and clinical candidates within its pipeline. Biomarin understands that the patients it treats are living with conditions where time is essential therefore the efficiency and speed of its research, development, manufacturing and commercialization is of prime importance.
Over the years Biomarin has partnered with some very reputable companies to access the technologies, products and programs it has required to get to where it is today. The company states that it relentlessly pursues early stage science so that it can identify and select opportunities that will eventually change the course of certain diseases. Within a year of being established Biomarin has signed a joint venture agreement with Genzyme to commercialize and develop its lead product at the time Aldurazyme.
The deals didn’t stop there; in 2005 Biomarin signed a late stage development agreement with Serono for two separate projects, it then went onto acquire Zacharon Pharmaceuticals where it gained two preclinical targets and invaluable glycobiology expertise. More recently and specifically over the past 5 years Biomarin has signed 13 partnering and licensing deals, see figure 1.
This period saw Biomarin acquire Lead Therapeutics in 2010 for $18million to gain access to its rare cancers drug and then go onto acquire the biological manufacturing plant from Pfizer in Cork, Ireland.
Figure 1: Biomarin partnering deals 2009 - 2014
Source: Current Agreements, 2014
In order to keep its position as one of the leading companies for rare and serious diseases Biomarin seeks technologies and drugs that target rare genetic diseases. These partnerships so far, involving individuals, research institutions and companies has helped Biomarin provide breakthrough treatments. To contact Biomarin with any potential partnering opportunities please use this page.
Biomarin Pharmaceuticals is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Other events with Biomarin Pharmaceuticals Pharmaceuticals presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Biomarin Pharmaceuticals in person visit Current Partnering’s Event calendar.
Contacting Biomarin Pharmaceuticals for partnering
Biomarin Pharmaceuticals can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Biomarin Pharmaceuticals Pharmaceuticals’ business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Biomarin Pharmaceuticals Pharmaceuticals website has details for contacting Biomarin Pharmaceuticals Pharmaceuticals.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Biomarin Pharmaceuticals business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Biomarin Pharmaceuticals Linkedin Page.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the partnering contacts page on Biomarin Pharmaceuticals website for potential partnering opportunities and general contact names.
Source: Current Agreements, 2014
Our report provides more detailed insight into the details of each deal.
See: Partnering Agreements with Biomarin 2009-2014
Biomarin partnering at Current Agreements
Full details on each deal can be found at CurrentAgreements (subscription required)
Summary profile data for Biomarin
Available reports from Current Partnering
Report: Partnering Agreements with Biomarin 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for Biomarin
Read: more on Biomarin company profile, recent partnering, M&A and financing news and articles
Report: Finding Biopharma Licensing and Collaboration Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk